Ulf Wiinberg - UCB SA Independent Director

UCBJY Stock  USD 58.22  1.22  2.14%   

Director

Mr. Ulf Wiinberg has served as Independent NonExecutive Director of UCB S.A. since April 28, 2016. He is Member of the Audit Committee of the Company . He is a pharmaceutical industry professional. He started as a sales representative at Lederle Laboratories in Sweden, which later was acquired by Wyeth. At Wyeth, he was President of the global consumer health care business, and later President for the European business and strategically responsible for biotechnology and vaccines. He served as a member of the management committee from 20022008. From 2008 to end of 2014, he was the CEO of Lundbeck, a Danish company focusing on brain diseases. During his career, he has worked on development and in production of pharmaceutical products and vaccines that can make a big difference for patients. He has also served on the boards of the industry associations for the pharmaceutical and consumer healthcare business, Pharma, Efpia and WSMI. He was Chairman of the Board of Hansa Medical, Board member at Alfa Laval and Board member at Agenus. since 2016.
Age 59
Tenure 8 years
Phone32 2 559 99 99
Webhttps://www.ucb.com

Ulf Wiinberg Latest Insider Activity

Tracking and analyzing the buying and selling activities of Ulf Wiinberg against UCB SA pink sheet is an integral part of due diligence when investing in UCB SA. Ulf Wiinberg insider activity provides valuable insight into whether UCB SA is net buyers or sellers over its current business cycle. Note, UCB SA insiders must abide by specific rules, including filing SEC forms every time they buy or sell UCB SA'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

UCB SA Management Efficiency

The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 1.97 B in total debt with debt to equity ratio (D/E) of 0.34, which is about average as compared to similar companies. UCB SA ADR has a current ratio of 1.1, suggesting that it may not have the ability to pay its financial obligations in time and when they become due. Debt can assist UCB SA until it has trouble settling it off, either with new capital or with free cash flow. So, UCB SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like UCB SA ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for UCB to invest in growth at high rates of return. When we think about UCB SA's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Kasim KutayNovo Nordisk AS
55
Thomas RantzauNovo Nordisk AS
46
Liz HewittNovo Nordisk AS
64
Christine PoonRegeneron Pharmaceuticals
65
Joseph GoldsteinRegeneron Pharmaceuticals
77
Thomas KoestlerNovo Nordisk AS
63
Bonnie BasslerRegeneron Pharmaceuticals
55
Elizabeth CorleyPearson PLC ADR
63
David AltshulerVertex Pharmaceuticals
53
Sally JohnsonPearson PLC ADR
51
Soeren PedersenNovo Nordisk AS
52
Joshua LewisPearson PLC ADR
53
Sylvie GregoireNovo Nordisk AS
59
George SingRegeneron Pharmaceuticals
68
Eivind KoldingNovo Nordisk AS
55
Vivienne CoxPearson PLC ADR
60
Mary SzelaNovo Nordisk AS
52
David GreenwayVertex Pharmaceuticals
34
Terrence KearneyVertex Pharmaceuticals
63
Nancy PhelanModerna
48
Stefan LorenModerna
50
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company was incorporated in 1925 and is headquartered in Brussels, Belgium. UCB S operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 8600 people. UCB SA ADR [UCBJY] is a Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading.

Management Performance

UCB SA ADR Leadership Team

Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee
Detlef Thielgen, CFO and Executive VP
Kay Davies, Independent Director
Dirk Teuwen, VP Corporate Societal Responsibility
Anna Richo, Executive VP and General Counsel
Viviane Monges, Independent Non-Executive Director
Gerhard Mayr, Non-Executive Chairman of the Board
Cyril Janssen, Director
Caroline Vancoillie, Chief Functions
Cedric Rijckevorsel, Director
JeanChristophe Tellier, Chairman of the Executive Committee, CEO
Arnoud Calesberg, Non-Executive Director
Mark McDade, COO and Executive VP
Xavier Michel, Vice President and Secretary General
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee
Bharat Tewarie, Executive Vice President Chief Marketing Officer
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director
Norman Ornstein, Non-Executive Independent Director
Jeff Wren, Executive Vice President Neurology – Patient Value Unit Head
JeanPierre Kinet, Non-Executive Independent Director
Antje Witte, VP of Investor Relations
Alice Dautry, Independent Director
Sandrine CFA, Ex CFO
Harriet Edelman, Non-Executive Independent Director
Ulf Wiinberg, Independent Director
William Silbey, Exec Counsel
Thomas McKillop, Non-Executive Independent Director
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee
France Nivelle, VP Global Communication
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee
Pierre Gurdjian, Independent Director
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board
Iris LoewFriedrich, Executive Vice President Chief Medical Officer
CharlesAntoine Janssen, Non-Executive Director
Pr LowFriedrich, Chief VP
Kirsten LundJurgensen, Ex Solutions
Albrecht Graeve, Non-Executive Independent Director
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee

UCB Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UCB SA ADR. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for UCB Pink Sheet analysis

When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Please note, there is a significant difference between UCB SA's value and its price as these two are different measures arrived at by different means. Investors typically determine if UCB SA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UCB SA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.